# name
Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis

# metadata.dc.description.abstract[].value
Among 56 patients with EGPA regularly controlled at our department, 11 patients were treated with mepolizumab because of corticodependence and unsatisfactory disease control. The mean time of treatment was 38 months (range: 3-66 months). Patients with persistent symptoms improved their asthma control, but 3 of them persisted with recurrent ENT symptoms in spite of treatment with mepolizumab. None of the patients developed vasculitic manifestations (cutaneous, neurological, gastrointestinal, renal) during treatment. All patients achieved a Birmingham Vasculitis Activity Score (BVAS) of 0 points at 12 months or earlier. In general, patients reduced the number of flares, which tended to be milder, and all related to asthma or ENT manifestations. The improvement in disease activity allowed notable glucocorticoid tapering.

# metadata.dc.relation.ispartof[].value
European Journal Of Internal Medicine, 2022

# metadata.dc.rights[].value
cc-by-nc-nd (c) Ríos Garcés, Roberto et al., 2022

# metadata.dc.source[].value
Articles publicats en revistes (Medicina)

# metadata.dc.title[].value
Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis